Focusing on Rare Diseases and Addressing Unmet Clinical Needs

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired clonal disorder of hematopoietic stem cells. The disease is primarily characterized by intravascular hemolysis, bone marrow failure, and venous thrombosis. Ongoing hemolysis may cause fatigue, renal impairment, pain, dyspnea, and other symptoms. Studies have shown that, before complement inhibitors became available, patients with PNH had a poor prognosis.

Conventional management of PNH primarily includes supportive care, prevention and treatment of thrombosis, and allogeneic hematopoietic stem cell transplantation; immunosuppressive therapy may be used in patients with concomitant bone marrow failure. According to the Chinese Guideline for the Diagnosis and Treatment of Paroxysmal Nocturnal Hemoglobinuria (2024 Edition), treatment of PNH should be based on clinical subtype, and complement inhibitors are recommended as first-line therapy for classic PNH.

Although advances in complement-targeted therapies have improved the treatment of PNH in recent years, patient needs remain largely unmet. C5 inhibitors can control intravascular hemolysis but do not block upstream complement activation. Some patients continue to experience residual anemia, fatigue, or a need for transfusions. Traditional twice-daily dosing regimens carry a risk of breakthrough hemolysis. Patients need new therapies that are effective, convenient, and suitable for long-term disease management.

Ciprocopan Succinate Tablets is a highly potent and selective small-molecule complement factor B (FB) inhibitor developed independently by Haisco with full intellectual property rights. Using a structure-based approach, Haisco's R&D team identified opportunities for optimization and incorporated metabolically stabilizing groups to shield metabolic soft spots at the source. By targeting a key step in the alternative complement pathway, the compound inhibits both pathway initiation and the alternative-pathway-mediated amplification loop, thereby suppressing activation of the complement system and delivering therapeutic efficacy in complement-mediated diseases.

As an innovative oral small-molecule therapy, Ciprocopan Succinate Tablets is administered once daily. No dosage adjustment is required in patients with mild or moderate renal impairment or in patients with mild, moderate, or severe hepatic impairment. No dosage adjustment is required when the product is coadministered with strong CYP2C8 inhibitors, and it may be taken without regard to food, improving treatment convenience and adherence.

Advancing Innovation and Expanding the Innovative Medicine Portfolio

Innovation is a core pillar of Haisco's strategy. From project initiation through clinical development, and from scientific exploration to successful commercialization, Ciprocopan Succinate Tablets represents a major milestone in Haisco's sustained investment in R&D and innovation.

Guided by its innovation and globalization strategy and supported by the strong innovation ecosystem and biopharmaceutical industry environment in Sichuan Province and Chengdu, Haisco continues to increase investment in innovation. The company has built an R&D team of more than 1,000 professionals focused on key therapeutic areas, including anesthesia and pain management, chronic and metabolic diseases, gastrointestinal and liver diseases, respiratory diseases, autoimmune diseases, and oncology. Annual R&D investment has exceeded RMB 1 billion for several consecutive years, accelerating the translation of innovation into products.

Haisco Pharmaceutical Group has established 5 modern manufacturing sites and more than 30 production lines across China to accelerate the industrialization of its innovative products. The Group has 27 Class 1 innovative drug programs and has established a tiered R&D pipeline spanning preclinical research and Phase I, Phase II, and Phase III clinical trials. Four Class 1 innovative drugs—Cipepofol Injection, Anrikefon, Cofrogliptin, and Crisugabalin—have received marketing approval, all of which are included in China's National Reimbursement Drug List (NRDL).

Cipepofol Injection, an innovative intravenous anesthetic with independent intellectual property rights, received marketing approval from the U.S. Food and Drug Administration (FDA) in late May of this year. It is the first China-originated intravenous anesthetic new drug to enter the global market, marking a breakthrough from "new in China" to "new for the world".

The successful approval and launch of Ciprocopan Succinate Tablets marks another breakthrough for Haisco in the frontier of global innovation in complement-mediated disease treatment and further enhances the company's innovative medicine portfolio.

International Partnerships: Taking China-Originated Innovation Global

Haisco is advancing its Innovation and Globalization Strategy 2.0, expanding its presence in global innovation markets, and continuously strengthening its international clinical development and global collaboration capabilities.

Ciprocopan Succinate Tablets is also a key program in Haisco's globalization strategy. In June 2026, Haisco entered into an Exclusive License Agreement with U.S.-based Nuvectis Pharma, Inc., granting Nuvectis exclusive rights to develop, manufacture, and commercialize HSK42360 (a BRAF inhibitor) globally outside Greater China, as well as exclusive rights to develop, manufacture, and commercialize HSK39297 (the ciprocopan succinate program) globally outside Greater China, Southeast Asia, and India.

As part of the consideration for the out-license transaction, Haisco will receive license payments for the HSK42360 and HSK39297 programs, including a total of $40 million in upfront and near-term milestone payments and up to $1.421 billion in additional milestone payments. Haisco will also be eligible to receive tiered royalties of up to double-digit percentages on future net product sales. Together, the companies will work to make these products available to more patients worldwide.

In recent years, Haisco has accelerated its globalization efforts and entered into innovative drug R&D collaborations and international licensing agreements with several global pharmaceutical companies, including AbbVie, Eli Lilly, and Nuvectis, across key areas such as oncology and autoimmune diseases. These collaborations are helping bring China-originated innovative medicines to international markets. China's innovative drug R&D capabilities are gaining increasing global recognition.

Looking ahead, Haisco will continue to pursue its innovation and globalization strategy, focus on major disease areas and unmet clinical needs, accelerate the development and global expansion of original innovative medicines, and further strengthen its independent innovation capabilities. The company aims to build an internationally competitive portfolio of innovative medicines, bring more China-originated therapies to patients worldwide, and contribute to the Healthy China initiative and global biopharmaceutical innovation.

Further Reading

 [About Paroxysmal Nocturnal Hemoglobinuria (PNH)]

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired clonal disorder of hematopoietic stem cells. Acquired PIGA mutations in hematopoietic stem cells cause deficiencies in complement-regulatory proteins, including CD55 and CD59, and constitute the principal molecular basis of complement-mediated intravascular hemolysis in PNH. PNH is primarily characterized by intravascular hemolysis, bone marrow failure, and venous thrombosis. Ongoing hemolysis may cause fatigue, renal impairment, pain, dyspnea, and other symptoms. Studies have shown that, before complement inhibitors became available, patients with PNH had a poor prognosis.

Conventional management of PNH primarily includes supportive care, prevention and treatment of thrombosis, and allogeneic hematopoietic stem cell transplantation; immunosuppressive therapy may be used in patients with concomitant bone marrow failure. According to the Chinese Guideline for the Diagnosis and Treatment of Paroxysmal Nocturnal Hemoglobinuria (2024 Edition), treatment of PNH should be based on clinical subtype, and complement inhibitors are recommended as first-line therapy for classic PNH.

 [Three Advances in the Clinical Benefits of Ciprocopan Succinate Tablets]

Enabled by deuterium substitution technology, Ciprocopan Succinate Tablets delivers three major advances in clinical benefit for PNH. A head-to-head Phase III study in China showed a hemoglobin target-attainment rate of 59.5%, a hemoglobin increase of 48.35 g/L, and reduced transfusion requirements; 94.6% of patients were transfusion-free, helping conserve healthcare resources. The incidence of treatment-emergent adverse events (TEAEs) was lower, and no adverse events led to treatment discontinuation or study withdrawal; the product also offers convenient once-daily oral dosing and a prolonged half-life of 21–38 hours.

 [Selected Scientific Conference Presentations on Ciprocopan Succinate Tablets]

Results from two Phase III clinical studies of Ciprocopan Succinate Tablets were accepted for presentation at the 2026 Congress of the European Hematology Association (EHA). One was a randomized controlled study in patients with PNH who were complement-inhibitor-naïve, and the other was a single-arm study in patients with persistent anemia despite stable treatment with a C5 monoclonal antibody.

These two studies included a broad population of patients with PNH and both yielded positive results, demonstrating robust efficacy and a favorable safety profile. Once-daily oral monotherapy with Ciprocopan Succinate Tablets may provide sustained and comprehensive disease control for patients with PNH, together with a favorable safety profile and the potential for long-term treatment, underscoring its innovative value and global competitiveness in PNH care.

 [References]

1. Red Blood Cell Diseases (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese Guideline for the Diagnosis and Treatment of Paroxysmal Nocturnal Hemoglobinuria (2024 Edition). Chinese Journal of Hematology, 2024, 45(8): 727-737. 
2. Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med, 1995, 333(19): 1253-1258.
3. Dingli D. Improved therapy for paroxysmal nocturnal hemoglobinuria. Ann Blood. 2026;11:8. doi:10.21037/aob-2025-1-62
4. Xu G, et al. Efficacy and safety of switching to oral HSK39297 monotherapy in paroxysmal nocturnal hemoglobinuria patients with persistent anemia despite anti-C5 therapy: a phase 3 study (HSK39297-302). Presented at EHA 2026; Abstract PS1786.
5. Phase III Clinical Study Report of HSK39297 Tablets
6. Prescribing Information for Ciprocopan Succinate Tablets;
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
8. Risitano AM, et al. Br J Haematol. 2022;196:288-303.
9. Hillmen P, et al. N Engl J Med. 2006;355:1233-1243.
10. Peffault de Latour R, et al. Blood. 2015;125(5):775-783.4. Panse J, et al. Value Health. 2023;26(Suppl):S468..
11. Dingli D, et al. Ann Hematol. 2022;101:251-263.

Disclaimer:

This material is intended to provide current medical information and research updates for healthcare professionals only. It is not intended for product promotion or advertising. The content herein is not a substitute for professional medical judgment and should not be construed as diagnostic or treatment advice. Healthcare professionals should refer to and strictly follow the most current full prescribing information when prescribing any product discussed herein. For the complete disclaimer, visit: https://www.haisco.com/statement.html.

HSK42360 is a best-in-class BRAF paradoxical breaker inhibitor designed to overcome acquired resistance to current BRAF inhibitors. It demonstrates strong potential in primary brain tumors and brain metastases and is currently being evaluated in a Phase I clinical trial in China. HSK39297 is a best-in-class potential once-daily (QD) CFB inhibitor. Two NDA applications for PNH have been submitted in China, while several additional indications are advancing through Phase 2 and Phase 3 clinical development in China.

"This collaboration is highly aligned with our global development strategy and is expected to generate sustainable value and long-term returns," said Dr. Pangke Yan, Chief Executive Officer of Haisco. "By partnering with a U.S. biotechnology company such as Nuvectis, Haisco aims to accelerate the global development of innovative oncology and complement therapies and bring high-quality treatment options to patients worldwide."

The collaboration strengthens Haisco's global presence and enhances the value of its pipeline by leveraging Nuvectis' proven research and development capabilities, extensive industry experience, and established track record in oncology and kidney diseases.

Under the terms of the agreement, Haisco will receive an upfront and near-term payment of USD $40 million and is eligible to receive up to USD $1.421 billion in additional development, regulatory, and commercial milestone payments, as well as tiered royalties on future net sales. The first four milestones may be payable by Licensee in cash and/or common stock, provided that the equity consideration shall represent less than 40% of the total milestone value. If the Licensee sublicenses all or part of the rights to a third party, or if a Change of Control occurs during the restricted period, Haisco shall be entitled to share in the corresponding sublicense income and Change-of-Control payments. In addition, the effectiveness of the agreement is subject to certain financing conditions which Nuvectis is required to meet to ensure sufficient capital for the development of the licensed products.

About Haisco

As a benchmark enterprise in China's innovative pharmaceutical sector, Haisco adheres to a core strategy of "innovation-driven growth and global expansion." The company has established a diversified R&D pipeline encompassing small-molecule innovative drugs, biologics, and high-end generics. Haisco is actively advancing more than 50 R&D programs across key therapeutic areas including pain management, oncology, respiratory diseases, autoimmune disorders, metabolic diseases, and central nervous system disorders; notably, over 10 of these programs have entered pivotal clinical stages. The company has maintained a strong commitment to R&D, with investment exceeding 15% of revenue in each of the past three years. It has established major R&D centers in Chengdu, Shanghai, and Silicon Valley, supported by a research team with extensive global experience, forming an integrated innovation system combining in-house capabilities and external collaboration.

As early as 2015, Haisco initiated its global strategy and has since actively expanded into international markets through multiple approaches, including license-out transactions, co-development partnerships, and overseas mergers and acquisitions.

Looking ahead, Haisco will continue to focus on areas of unmet medical need, strengthen its capabilities in independent innovation and global collaboration, and strive to deliver high-quality, China-originated innovative medicines to patients around the world.

Under the agreement, Haisco will be responsible for the discovery and identification of up to five innovative target programs, while Lilly will lead IND-enabling studies, clinical development, and commercialization. Lilly will obtain exclusive worldwide rights to certain programs, and exclusive rights outside mainland China, Hong Kong, Macau, and Taiwan (the "Haisco Territory") for certain other programs, while Haisco will retain rights within the Haisco Territory for those programs.

"This collaboration is highly aligned with our international development strategy and is expected to generate sustainable value and long-term returns," said Dr. Pangke Yan, chief executive officer of Haisco, "By partnering with a global biopharmaceutical leader such as Lilly, Haisco aims to accelerate the global development of innovative therapies and deliver high-quality treatment options to patients worldwide."

This collaboration reflects the first license and research collaboration between Haisco and Lilly. By leveraging each party's strengths in innovative drug development, the two companies will work together to accelerate the global advancement of innovative therapeutics.

Haisco will be eligible to receive up to $87M in upfront and near-term payments, up to $2,967M in all remaining downstream milestones, as well as single-digit tiered royalties on future product sales.

About Haisco

As a benchmark enterprise in China's innovative pharmaceutical sector, Haisco adheres to a core strategy of "innovation-driven growth and global expansion." The company has established a diversified R&D pipeline encompassing small-molecule innovative drugs, biologics, and high-end generics. Haisco is actively advancing more than 50 R&D programs across key therapeutic areas including pain management, oncology, respiratory diseases, autoimmune disorders, metabolic diseases, and central nervous system disorders; notably, over 10 of these programs have entered pivotal clinical stages. The company has maintained a strong commitment to R&D, with investment exceeding 15% of revenue in each of the past three years. It has established major R&D centers in Chengdu, Shanghai, and Silicon Valley, supported by a research team with extensive global experience, forming an integrated innovation system combining in-house capabilities and external collaboration.

As early as 2015, Haisco initiated its global strategy and has since actively expanded into international markets through multiple approaches, including license-out transactions, co-development partnerships, and overseas mergers and acquisitions.

Looking ahead, Haisco will continue to focus on areas of unmet medical need, strengthen its capabilities in independent innovation and global collaboration, and strive to deliver high-quality, China-originated innovative medicines to patients around the world.

Intravenous anesthetics are the cornerstone of clinical surgeries and intensive care. For decades, clinical challenges associated with intravenous anesthesia—such as injection pain and respiratory depression—have remained persistent obstacles that the global pharmaceutical research community has strived to overcome.

Cipepofol (Chinese trade name: Sishuning) is China's first independently developed Class 1 innovative intravenous anesthetic with global independent intellectual property rights. It has been approved in China for sedation and anesthesia in non-tracheal intubation surgeries/procedures, induction and maintenance of general anesthesia, and sedation during mechanical ventilation in the intensive care unit. In September 2025, its approval was further expanded to include the induction and maintenance of general anesthesia in children and adolescents.

The development of Cipepofol dates back to 2012. Haisco's R&D team tackled numerous challenges to refine the molecular structure. By introducing a chiral cyclopropyl group and conducting thousands of screenings and safety evaluations, they successfully developed a Class 1 new drug that demonstrated favorable efficacy and safety profiles.

Results from clinical studies conducted both domestically and internationally showed that, while retaining the advantages of rapid onset and complete recovery, Cipepofol significantly reduced the incidence of intraoperative respiratory depression and cardiovascular adverse reactions, as well as injection pain. With a lower risk of respiratory depression, more stable hemodynamics, milder injection pain, and individualized care for elderly and pediatric patients, Cipepofol not only makes "comfortable treatment" more compassionate—directly addressing patients' desire for a pain-free anesthesia induction and reducing their fear of surgery—but also substantially enhances the comfort and safety of the diagnosis and treatment process on both physiological and psychological levels, while greatly improving the accuracy and success rate of physicians' diagnoses and treatments.

In December 2020, Cipepofol was officially approved for marketing by the National Medical Products Administration (NMPA), ushering in a new chapter in clinical comfortable anesthesia. Subsequently, multiple indications were approved in succession, including induction of general anesthesia, fiberoptic bronchoscopy, and sedation during intensive care. In September 2025, the dosage and administration for the induction and maintenance of general anesthesia in children and adolescents were approved, further broadening its clinical application scenarios.

As of May 2026, Cipepofol has been incorporated into the recommendations of over 20 guidelines and consensus documents, as well as into textbooks for higher education under China's 14th Five-Year Plan, and has been included in the National Reimbursement Drug List (NRDL). To date, it has been adopted by over 3,300 medical institutions, cumulatively benefiting more than 40 million patient visits.

The internationalization journey of Cipepofol epitomizes the shift from "Made in China" to "Innovated in China". After receiving FDA clearance to conduct clinical trials in 2021, Cipepofol was granted a waiver for Phase II trials in the United States and advanced directly to pivotal Phase III trials. All clinical studies were completed in 2024, yielding superior results in a head-to-head comparison against the standard of care. In July 2025, driven by its exceptional innovative strength and solid clinical evidence, the New Drug Application (NDA) for Cipepofol was formally accepted by the U.S. FDA.

The successful U.S. FDA marketing approval of Cipepofol (CYPSEDO) stands as a powerful testament to the overseas capabilities of Chinese pharmaceutical enterprises. Seizing the opportunity presented by the FDA approval of Cipepofol (CYPSEDO), Haisco is actively advancing its commercialization in the United States and other regions through collaborations. The company will also consider initiating a marketing authorization application in Europe at an appropriate time, delivering high-quality solutions originating from Chinese innovative drugs to the world and benefiting more global patients.

About Haisco

Haisco is an international pharmaceutical enterprise integrating research and development, manufacturing, and sales (Stock Code: 002653.SZ). Focusing on therapeutic areas such as anesthesia and analgesia, chronic metabolic diseases, respiratory and autoimmune diseases, neurological systems, and oncology, the company adheres to an innovation and globalization strategy. With the vision of "striving to become the most trusted international pharmaceutical enterprise", it aims to meet unmet clinical needs and care for patients worldwide. Currently, Haisco Pharmaceutical Group has established a series of diversified R&D pipelines with independent intellectual property rights, covering small-molecule innovative drugs, biologics, and high-end generics. Multiple projects are in the clinical development stage, and several innovative drugs have been commercialized, providing diversified innovative product solutions globally.

Appendix: Background Information on CYPSEDO (cipepofol)

I. Published SCI Papers Related to CYPSEDO (cipepofol) with Impact Factor >6

1. Ni T, Zhou X, Wu S, et al. Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial. JAMA Surg. 2025;14.9(IF).
2. Yu Y, Deng J, Yin Y,et al.  Ciprofol vs propofol for gastrointestinal endoscopy sedation: a systematic review and meta-analysis. Int J Surg. 2025;10.1(IF).
3. He ZZ, Liang JY, Duan JX, et al. Ciprofol versus propofol sedation in ICU patients and norepinephrine requirements: a single-center prospective cohort study. Crit Care. 2025;9.3(IF).
4. Gan TJ, Bertoch T, Habib AS, et al. Comparison of the efficacy of HSK3486 and propofol for induction of general anesthesia in adults: a multicenter, randomized, double-blind, controlled, phase 3 noninferiority trial. Anesthesiology. 2024;9.1(IF).
5. Liu YJ, Peng Z, Liu S, et al. Efficacy and safety of ciprofol sedation in ICU patients undergoing mechanical ventilation: A multicenter, single-blind, randomized, noninferiority trial. Crit Care Med. 2023;8.3(IF).
6. Liu YJ, Zuo LY, Li XY, et al. Early sedation using ciprofol for intensive care unit patients requiring mechanical ventilation: a pooled post-hoc analysis of data from phase 2 and phase 3 trials. Ann Intensive Care. 2024;7.8(IF).
7. Qin LL, Ren L, Wan SL, et al. Design, synthesis, and evaluation of novel 2,6-disubstituted phenol derivatives as general anesthetics. J Med Chem. 2017;7.3(IF).
8. Liang P, Dai M, Wang X, et al. Efficacy and safety of ciprofol vs. propofol for the induction and maintenance of general anaesthesia: A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial. Eur J Anaesthesiol. 2023;6.8(IF).
9. Ding YY, Long YQ, Yang HT, et al. Efficacy and safety of ciprofol for general anaesthesia induction in elderly patients undergoing major noncardiac surgery: A randomised controlled pilot trial. Eur J Anaesthesiol. 2022;6.8(IF).
10. Liu YJ, Yu XY, Zhu DM, et al. Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial. Chin Med J. 2022;6.1(IF).

II. International Academic Conferences Where CYPSEDO (cipepofol) Was Presented

1. ISAP 31^st Annual Meeting - 2022 - Poster
2. WCA - 2024- Lecture & LBA ePoster & ePoster
3. ESA Annual Meeting - 2024 - ePoster
4. JSA Annual Meeting - 2024 - Poster
5. ASA Annual Meeting - 2025 - Oral & ePoster
6. ESICM LIVES - 2024 - Poster
7. ESA Annual Meeting - 2025 - Lecture & ePoster
8. SCCM Critical Care Congress - 2025 - Poster
9. ESICM LIVES - 2025 - Oral & Poster
10. AACA Annual Meeting - 2025 -  Lecture
11. ESA Annual Meeting - 2026 - ePoster

III. Clinical Guidelines and Consensus Statements Incorporating CYPSEDO (cipepofol)

1. Expert Consensus on Sedation/Anesthesia for Bronchoscopy (2020 Edition), 2020, Chinese Society of Anesthesiology
2. Chinese Expert Consensus on Sedation/Anesthesia for Digestive Endoscopy (2020 Edition), 2020, Anesthesia Collaborative Group of the Chinese Society of Digestive Endoscopy
3. Guidelines for Anesthesia in Ambulatory Surgery (2023 Edition), 2023, Chinese Society of Anesthesiology
4. Expert Consensus on Out-of-Operating Room Anesthesia/Sedation in Elderly Patients (2023 Edition), 2023, Journal of Clinical Anesthesiology
5. Guidance on Sedation and Anesthesia Protocols for Diagnostic and Therapeutic Procedures (2023 Edition), 2023, Chinese Society of Anesthesiology
6. Expert Consensus on Analgesia and Sedation in Patients with Severe Neurological Diseases (2023 Edition), 2023, Expert Group on Analgesia and Sedation for Severe Neurological Diseases
7. Diagnostic and Therapeutic Process for Analgesia and Sedation in Adult Critically Ill Patients, 2023, Chinese Journal of Critical Care Medicine (Electronic Edition)
8. Expert Consensus on Data Elements and Definitions for Analgesia and Sedation in Adult Critically Ill Patients (2023 Edition), 2023, Expert Group on Data Elements and Definitions for Analgesia and Sedation in Adult Critically Ill Patients
9. Expert Consensus on Post-Intensive Care Management (2023 Edition), 2023, Chinese Society of Critical Care Medicine
10. Standards for Diagnosis and Treatment of Non-Neonatal Tetanus (2024 Edition), 2024, General Office of the National Health Commission
11. Chinese Clinical Practice Guidelines for Total Intravenous Anesthesia (2024 Edition), 2024, Chinese Society of Anesthesiology
12. Chinese clinical practice guidelines for total intravenous anaesthesia:a systematic review and expert consensus-based recommendations，2025，e Chinese Society of Anaesthesiology of the Chinese Medical Association.
13. Expert Consensus on Medication Adjustment During ECMO Support (2025), 2025, Critical Care Medicine Committee of China International Exchange and Promotive Association for Medical and Health Care, Hospital Pharmacy Committee of Chinese Pharmaceutical Association
14. Expert Recommendations for Out-of-Operating Room Anesthesia/Sedation in Patients with Obesity, 2025, Task Force on "Expert Recommendations for Out-of-Operating Room Anesthesia/Sedation in Patients with Obesity"
15. Expert Consensus on Anesthesia Management for ERCP (2025), 2025, Chinese Society of Digestive Endoscopy, Anesthesiology Branch of Chinese Geriatrics Society
16. Expert Consensus on the Use of Intravenous Anesthetics for Refractory Insomnia Disorder, 2025, Psychiatric Health Branch of Sichuan Preventive Medicine Association, Sleep Medicine Committee of Sichuan Geriatrics Society
17. Emergency Expert Consensus on Diagnosis and Treatment of Sepsis-Associated Encephalopathy in the Elderly, 2025, Emergency Medicine Branch of Chinese Medical Association, Emergency Branch of Chinese Geriatrics Society, Emergency Medicine Branch of Beijing Medical Association
18. Expert Consensus on Analgesia, Sedation, and Delirium Management in Adult Patients Receiving Extracorporeal Membrane Oxygenation (2025 Edition), 2025, Extracorporeal Life Support Committee of Chinese Medical Doctor Association, Chinese Society of Anesthesiology
19. Expert Consensus on the Application of Drug-Induced Sleep Endoscopy in the Diagnosis and Treatment of Obstructive Sleep Apnea (2025 Edition), 2025, Sleep Breathing Disorders Working Committee of the Respiratory Physician Branch of Chinese Medical Doctor Association
20. Clinical Practice Guideline for the Use of Intravenous Anesthetics (2025 Edition), 2025, Anesthesiologist Branch of Chinese Medical Doctor Association
21. Chinese Guidelines for Sedation and Anesthesia Management During Digestive Endoscopy (2026 Edition), 2026, Chinese Society of Digestive Endoscopy / Chinese Society of Anesthesiology

The program includes multiple compounds designed to address pain-related indications. These compounds are currently at various development stages in China, ranging from preclinical to Phase 1 clinical development.

"This collaboration is highly aligned with our international development strategy and is expected to generate sustainable value and long-term returns," said Dr. Pangke Yan, chief executive officer of Haisco. "By partnering with a global biopharmaceutical leader such as AbbVie, Haisco aims to accelerate the global development of innovative pain therapies and deliver high-quality treatment options to patients worldwide."

The collaboration strengthens Haisco's global presence and pipeline by leveraging AbbVie's development and commercialization capabilities, as well as its recognized expertise in neuroscience.

Haisco will receive an upfront payment of USD $30 million and is eligible to receive up to USD $715 million in aggregate development, regulatory, and commercial milestone payments. In addition, Haisco is eligible to receive tiered royalties on future net sales.

About Haisco

As a benchmark enterprise in China's innovative pharmaceutical sector, Haisco adheres to a core strategy of "innovation-driven growth and global expansion." The company has established a diversified R&D pipeline encompassing small-molecule innovative drugs, biologics, and high-end generics. Haisco is actively advancing more than 50 R&D programs across key therapeutic areas including pain management, oncology, respiratory diseases, autoimmune disorders, metabolic diseases, and central nervous system disorders; notably, over 10 of these programs have entered pivotal clinical stages. The company has maintained a strong commitment to R&D, with investment exceeding 15% of revenue in each of the past three years. It has established major R&D centers in Chengdu, Shanghai, and Silicon Valley, supported by a research team with extensive global experience, forming an integrated innovation system combining in-house capabilities and external collaboration.

As early as 2015, Haisco initiated its global strategy and has since actively expanded into international markets through multiple approaches, including out-licensing transactions, co-development partnerships, and overseas mergers and acquisitions.

Looking ahead, Haisco will continue to focus on areas of unmet medical need, strengthen its capabilities in independent innovation and global collaboration, and strive to deliver high-quality, China-originated innovative medicines to patients around the world.